No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
128 |
4. Check minimum number of eventsNone |
128 |
5. Include endpointsNone |
128 |
6. Filter based on genotype QC (FinnGen only) |
128 |
Control definitions (FinnGen only)
- Control exclude
- D3_IMMUNEMECHANISM
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D80
- Name in latin
- Hypogammaglobulinaemia hereditaria
Similar endpoints
↥List of similar endpoints to
Hereditary hypogammaglobulinemia
based on the number of shared cases.
Similar with more cases:
- Immunodeficiency with predominantly antibody defects
- Immunodeficiencies
- Certain disorders involving the immune mechanism
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 605 | 359 | 244 |
| Only index persons | 530 | 325 | 205 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 42.72 | 45.82 | 38.04 |
| Only index persons | 42.31 | 45.45 | 37.32 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 128 | 80 | 48 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.02 |
| Median age at first event (years) | 45.89 | 47.16 | 43.78 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 113
- Matched controls
- 1128
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D80.0
ICD-10 Finland
Hereditary hypogammaglobulinaemia
+∞
149.9
108
*
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
+∞
67.6
58
*
120
Kela drug reimbursment
Hypogammaglobulinaemia
+∞
63.7
55
*
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
+∞
58.5
51
*
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
42.4
38
*
D80.8
ICD-10 Finland
Other immunodeficiencies with predominantly antibody defects
+∞
36.4
33
*
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
20.2
31.1
49
41
D80.3
ICD-10 Finland
Selective deficiency of immunoglobulin G [IgG] subclasses
+∞
30.6
28
*
ZX120
NOMESCO Finland
Intravenous
15.5
27.7
49
53
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
25.5
26.2
37
21
J01MA12
ATC
levofloxacin; systemic
10.7
26.2
60
108
WW200
NOMESCO Finland
Immunization
42.0
25.3
31
10
H02AB06
ATC
prednisolone; systemic
9.6
24.4
93
367
J01MA14
ATC
moxifloxacin; systemic
14.3
24.4
44
48
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
28.6
22.3
30
14
TPH04
NOMESCO Finland
Cathetrisation of vein
8.1
21.7
60
138
TDM10
NOMESCO Finland
Puncture of maxillary antrum
23.2
21.6
31
18
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.8
19.9
80
297
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
30.2
19.7
26
11
6BA02
NOMESCO Finland
NA
+∞
19.3
18
*
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
15.5
19.1
32
28
J47
ICD-10 Finland
Bronchiectasis
54.0
19.0
22
5
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
16.0
18.8
31
26
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
15.8
17.6
29
24
J18.9
ICD-10 Finland
Pneumonia, unspecified
7.0
17.6
51
118
R50.9
ICD-10 Finland
Fever, unspecified
8.1
17.3
43
79
D83.0
ICD-10 Finland
Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
+∞
17.1
16
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
14.0
16.7
29
27
J01FA06
ATC
roxithromycin; oral
5.7
16.6
80
338
J45.9
ICD-10 Finland
Asthma, unspecified
6.8
16.5
48
110
D83.9
ICD-10 Finland
Common variable immunodeficiency, unspecified
+∞
16.0
15
*
C01CA24
ATC
epinephrine; parenteral
9.5
15.7
34
49
J01.0
ICD-10 Finland
Acute maxillary sinusitis
5.7
15.5
56
166
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
5.6
15.2
56
169
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
11.1
14.9
29
34
H02AB07
ATC
prednisone; oral
6.6
14.2
41
90
R4110
NOMESCO Finland
Physiotherapy
5.3
14.1
53
161
TGC00
NOMESCO Finland
Bronchial lavation
26.4
13.4
18
8
J32.4
ICD-10 Finland
Chronic pansinusitis
79.0
12.9
14
*
Z01.8
ICD-10 Finland
Other specified special examinations
5.0
12.9
50
154
R03AC13
ATC
formoterol; inhalant
13.4
12.7
22
20
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.1
12.5
29
46
J01FA10
ATC
azithromycin; systemic
5.1
12.3
93
538
R03AK06
ATC
salmeterol and fluticasone; inhalant
5.8
11.9
37
87
R03DC03
ATC
montelukast; oral
5.3
11.7
40
105
UDH02
NOMESCO Finland
Rhinopharyngoscopy
8.1
11.7
27
42
J01FA09
ATC
clarithromycin; systemic
4.3
11.7
62
251
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
133.0
11.7
12
*
J45.1
ICD-10 Finland
Nonallergic asthma
8.3
11.5
26
39
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
4.9
11.5
43
125
N02AX02
ATC
tramadol; systemic, rectal
4.1
11.4
68
303
R03BA02
ATC
budesonide; inhalant
5.1
11.4
41
114
J01FA15
ATC
telithromycin; oral
6.0
11.3
33
72
J01MA02
ATC
ciprofloxacin; systemic
4.1
11.2
63
266
H02AB04
ATC
methylprednisolone; systemic
5.5
11.2
36
88
J45.0
ICD-10 Finland
Predominantly allergic asthma
6.9
11.1
29
54
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
4.7
11.1
44
135
M05BA04
ATC
alendronic acid; oral
10.9
11.1
21
23
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.7
11.0
34
79
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
120.8
10.6
11
*
2790A
ICD-9 Finland
Disorders involving the immune mechanism, Deficiency of humoral immunity[AGAMMAGLOBULINAEMIA (BRUTON)]
+∞
10.6
10
*
A07AA02
ATC
nystatin; oral
9.3
10.2
21
27
A46
ICD-10 Finland
Erysipelas
6.0
10.1
29
61
J32.9
ICD-10 Finland
Chronic sinusitis, unspecified
22.5
10.1
14
7
R03AC12
ATC
salmeterol; inhalant
12.3
9.7
17
16
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
+∞
9.5
9
*
ZXA00
NOMESCO Finland
Right side
4.0
9.5
47
172
R03BB04
ATC
tiotropium bromide; inhalant
6.4
9.3
25
48
J01DA06
ATC
[U] cefuroxime; systemic
4.7
9.3
34
94
JN4BD
NOMESCO Finland
Extensive body CT
6.1
9.3
26
53
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
4.9
9.2
32
84
R03BB01
ATC
ipratropium bromide; inhalant
20.7
9.2
13
7
R03DA04
ATC
theophylline; systemic, rectal
10.9
9.2
17
18
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
7.1
9.0
22
37
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
6.3
9.0
24
46
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.5
8.9
54
233
XF400
NOMESCO Finland
ECG with 12 standard connections
4.5
8.7
33
94
X59
ICD-10 Finland
Exposure to unspecified factor
4.1
8.6
37
119
H04.10
ICD-10 Finland
Dry eye syndrome
5.5
8.6
26
58
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
4.1
8.5
37
120
A28
ICPC
Limited function/disability NOS
6.1
8.5
23
45
M36.8*D80.1
ICD-10 Finland
Systemic disorders of connective tissue in hypogammaglobulinaemia
+∞
8.4
8
*
J06BA02
ATC
immunoglobulins, normal human, for intravascular adm.; systemic
+∞
8.4
8
*
D86.0
ICD-10 Finland
Sarcoidosis of lung
+∞
8.4
8
*
D83.8
ICD-10 Finland
Other common variable immunodeficiencies
+∞
8.4
8
*
J01FF01
ATC
clindamycin; systemic
3.5
8.3
49
203
H02AB09
ATC
hydrocortisone; systemic
19.0
8.3
12
7
R03AK07
ATC
formoterol and budesonide; inhalant
3.8
8.1
39
138
ZX112
NOMESCO Finland
Subcutaneous
14.5
8.1
13
10
R01AD09
ATC
mometasone; nasal
3.2
7.9
72
403
J46
ICD-10 Finland
Status asthmaticus
11.2
7.8
14
14
R03BA05
ATC
fluticasone; inhalant
3.7
7.7
37
130
B01AB05
ATC
enoxaparin; parenteral
3.5
7.7
43
168
J02AC01
ATC
fluconazole; systemic
3.1
7.6
65
343
WX002
NOMESCO Finland
Sedation and analgesia
4.0
7.5
32
101
A01AB09
ATC
miconazole; local oral
5.1
7.5
24
57
R01AD05
ATC
budesonide; nasal
6.5
7.5
19
34
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.9
7.5
33
108
R01AD08
ATC
fluticasone; nasal
3.2
7.5
52
239
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
4.8
7.4
25
63
R03AK03
ATC
[D] fenoterol & other drugs for obstructive airway dis; inhalant
8.9
7.4
15
19
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
+∞
7.4
7
*
GD1CG
NOMESCO Finland
Extensive examination of lungs and pleura with high intensity magnet
+∞
7.4
7
*
R06.0
ICD-10 Finland
Dyspnoea
3.5
7.3
39
148
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.1
7.3
23
54
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
6.1
7.2
19
36
WX408
NOMESCO Finland
General anesthesy, balanced
3.3
7.2
44
185
J01DA08
ATC
[U] cefaclor; oral
4.4
7.1
26
71
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
15.0
7.1
11
8
J05AB01
ATC
aciclovir; systemic
3.5
7.0
37
138
N03AX16
ATC
pregabalin; oral
3.4
7.0
40
158
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
10.3
7.0
13
14
TAB00
NOMESCO Finland
Lumbar puncture
8.1
7.0
15
21
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
3.0
6.9
74
442
UJF32
NOMESCO Finland
Coloscopy
3.3
6.9
40
161
R03AC02
ATC
salbutamol; inhalant
2.9
6.8
77
475
J01AA02
ATC
doxycycline; systemic
3.9
6.8
99
729
J01DA01
ATC
[U] cefalexin; systemic
3.1
6.7
85
562
R03AK11
ATC
formoterol and fluticasone; inhalant
13.4
6.7
11
9
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.2
6.7
26
75
R03BA08
ATC
ciclesonide; inhalant
5.0
6.7
21
49
R06AE07
ATC
cetirizine; oral
2.8
6.6
65
368
XW000
NOMESCO Finland
Bone marrow biopsy
9.0
6.5
13
16
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
15.5
6.5
10
7
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
4.0
6.5
27
83
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
6.1
6.5
17
32
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
10.2
6.5
12
13
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
12.0
6.4
11
10
C10AC01
ATC
colestyramine; oral
12.0
6.4
11
10
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.5
6.4
16
28
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.3
6.4
24
67
P01AB01
ATC
metronidazole; oral, rectal
2.8
6.4
61
333
S18
ICPC
Laceration/cut
2.8
6.4
56
291
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.9
6.3
27
85
D80.6
ICD-10 Finland
Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinaemia
+∞
6.3
6
*
132
Kela drug reimbursment
Sarcoidosis
+∞
6.3
6
*
D80.2
ICD-10 Finland
Selective deficiency of immunoglobulin A [IgA]
+∞
6.3
6
*
WE300
NOMESCO Finland
Profylactive therapy of malignancy with biomoidiers
+∞
6.3
6
*
D86.2
ICD-10 Finland
Sarcoidosis of lung with sarcoidosis of lymph nodes
+∞
6.3
6
*
GD1DG
NOMESCO Finland
Extremely extensive MRI examination of pleura with high field magnet
+∞
6.3
6
*
J01.1
ICD-10 Finland
Acute frontal sinusitis
13.6
6.2
10
8
R01AD01
ATC
beclometasone; nasal
3.6
6.2
29
99
C03CA01
ATC
furosemide; systemic
3.3
6.1
33
125
R03BA01
ATC
beclometasone; inhalant
3.7
6.1
27
88
J01DC02
ATC
cefuroxime; systemic
6.5
6.1
15
26
L08.9
ICD-10 Finland
Local infection of skin and subcutaneous tissue, unspecified
16.1
6.0
9
6
4730A
ICD-9 Finland
Chronic sinusitis, Maxillary
16.1
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
36
61
7.82
21.80
2.4
1.8
—
—
—
0
0
27
33
10.10
21.35
3.1
1.5
—
—
—
0
0
52
137
5.71
19.98
3.7
1.8
—
—
—
0
0
22
22
11.87
19.95
1.5
1.2
—
—
—
0
0
41
98
5.68
17.32
2.8
1.4
—
—
—
0
0
20
22
10.59
16.89
2.6
2.0
—
—
—
0
0
40
97
5.54
16.57
2.8
1.5
—
—
—
0
0
19
21
10.45
15.96
2.6
2.0
—
—
—
0
0
17
17
11.38
15.25
1.9
1.2
—
—
—
0
0
18
20
10.31
15.03
2.4
2.1
—
—
—
0
0
92
455
4.63
14.71
10.8
8.0
1.2
1.2
mmol/l
1.04
84
383
17
18
10.74
14.66
2.7
1.9
—
—
—
0
0
17
6
32.30
13.34
3.5
1.0
—
—
—
0
0
17
6
32.30
13.34
3.5
1.0
—
—
—
0
0
57
216
3.95
12.96
4.0
2.2
3.2
3.0
mg/l
0.25
57
190
37
103
4.65
12.75
7.8
8.3
1.1
1.1
mmol/l
0.07
37
96
31
75
5.13
12.64
5.7
4.5
6.0
5.8
kpa
0.23
31
75
16
20
9.00
12.16
1.6
1.7
—
—
—
0
0
17
23
8.37
12.15
10.6
4.8
53.9
57.9
%
0.43
17
23
17
23
8.37
12.15
10.0
3.8
3.3
4.9
e9/l
1.07
17
23
16
8
22.58
11.46
5.1
3.0
—
—
—
0
0
13
14
10.22
10.95
3.8
1.7
—
—
—
0
0
13
14
10.22
10.95
3.8
1.7
—
—
—
0
0
13
14
10.22
10.95
3.8
1.7
—
—
—
0
0
14
18
8.61
10.35
1.6
1.0
—
—
—
0
0
14
18
8.61
10.35
1.6
1.0
—
—
—
0
0
12
13
10.08
10.03
2.9
1.7
—
—
—
0
0
23
52
5.17
10.02
2.1
1.6
—
—
—
0
0
60
271
3.29
9.89
5.2
2.8
0.2
0.4
e6/l
0.73
50
191
40
140
3.70
9.87
2.6
1.9
28.5
29.0
s
0.28
40
135
11
11
10.85
9.68
2.8
1.8
—
—
—
0
0
12
14
9.35
9.50
4.1
1.7
—
—
—
0
0
55
241
3.25
9.46
2.1
1.7
0.9
1.4
mg/l
0.56
49
189
95
576
3.52
9.30
9.3
4.8
7.1
6.5
mmol/l
1.29
95
527
12
15
8.72
9.01
4.1
1.7
—
—
—
0
0
12
15
8.72
9.01
4.1
1.7
—
—
—
0
0
21
48
5.04
9.00
11.4
6.4
24.9
25.6
mmol/l
0.23
21
48
20
44
5.20
8.94
2.1
1.3
—
—
—
0
0
13
8
17.89
8.76
4.6
2.1
—
—
—
0
0
14
22
7.02
8.72
3.6
1.6
—
—
—
0
0
40
152
3.37
8.59
6.9
3.9
0.8
0.8
mmol/l
2.21
40
145
68
357
2.93
8.25
6.0
2.9
—
—
—
0
0
12
7
18.72
8.25
1.6
2.1
—
—
—
0
0
27
87
3.67
7.38
4.2
3.4
—
—
—
0
0
7
0
+∞
7.36
1.4
0.0
—
—
—
0
0
10
13
8.26
7.22
1.1
1.2
—
—
—
0
0
11
8
14.88
7.03
5.4
2.1
—
—
—
0
0
26
88
3.45
6.57
10.0
13.4
1.6
1.3
mmol/l
0.09
20
72
10
15
7.15
6.41
3.3
1.8
—
—
—
0
0
11
19
6.24
6.22
1.1
1.2
386.2
432.3
mg/l
0.36
11
19
12
24
5.41
5.87
1.1
1.0
—
—
—
0
0
15
37
4.46
5.81
2.3
1.1
—
—
—
0
0
21
69
3.44
5.52
3.4
4.9
76.6
83.6
ng/l
0.21
21
63
14
35
4.37
5.32
6.6
2.0
—
—
—
0
0
75
482
2.34
5.22
5.6
4.4
—
—
—
0
0
18
56
3.58
5.12
9.8
4.6
5.1
5.1
kpa
0.15
18
49
34
154
2.64
5.11
3.9
2.5
1.7
3.0
e6/l
0.59
22
81
10
20
5.34
4.86
1.6
1.5
—
—
—
0
0
61
371
2.23
4.70
2.5
1.8
94.7
99.5
pmol/l
0.42
33
181
34
160
2.53
4.70
3.7
2.4
0.9
0.9
e6/l
0.09
22
86
7
5
14.69
4.63
1.1
1.2
120.9
56.2
u/l
—
7
5
12
30
4.31
4.55
2.2
1.1
0.0
0.0
g/l
0.00
12
30
16
51
3.44
4.38
2.5
3.6
121.8
130.5
g/l
0.50
16
51
10
23
4.63
4.17
1.3
1.3
—
—
—
0
0
8
10
8.44
4.12
1.1
1.4
—
—
—
0
0
45
253
2.20
4.11
3.5
2.6
—
—
—
0
0
7
7
10.48
4.06
2.4
2.3
—
—
—
0
0
7
7
10.48
4.06
2.4
2.3
—
—
—
0
0
7
7
10.48
4.06
2.4
2.3
—
—
—
0
0
7
7
10.48
4.06
2.4
2.3
—
—
—
0
0
9
15
6.36
3.89
3.3
1.8
—
—
—
0
0
13
39
3.60
3.88
3.7
3.3
25.8
25.0
mmol/l
0.41
13
39
18
69
2.87
3.65
3.0
3.4
4.0
4.4
pmol/l
1.03
18
63
12
36
3.57
3.57
5.8
2.4
—
—
—
0
0
6
6
10.41
3.53
2.5
2.3
—
—
—
0
0
6
6
10.41
3.53
2.5
2.3
—
—
—
0
0
6
6
10.41
3.53
2.5
2.3
—
—
—
0
0
6
6
10.41
3.53
4.8
1.8
25.2
29.5
umol/l
—
6
6
32
166
2.24
3.50
4.9
3.1
242.1
36.2
ng/l
0.57
22
111
10
27
3.93
3.42
1.8
2.1
—
—
—
0
0
7
10
7.33
3.41
2.4
2.2
—
—
—
0
0
7
10
7.33
3.41
1.7
1.1
—
—
—
0
0
7
10
7.33
3.41
2.4
2.2
—
—
—
0
0
7
10
7.33
3.41
2.4
2.2
—
—
—
0
0
13
43
3.25
3.36
3.1
3.8
54.8
50.7
%
0.19
13
43
10
28
3.79
3.26
2.4
1.1
0.0
0.0
g/l
—
10
28
10
28
3.79
3.26
2.4
1.1
0.0
0.0
g/l
—
10
28
118
1013
3.11
3.21
34.7
11.5
86.5
86.3
ml/min/173m2
0.02
110
815
8
16
5.26
3.10
1.3
1.3
—
—
—
0
0
6
8
7.80
3.09
1.5
2.6
—
—
—
0
0
6
8
7.80
3.09
2.5
1.3
—
—
—
0
0
110
920
2.39
3.04
48.7
15.0
14.2
13.6
%
3.70
110
909
12
42
3.05
2.83
2.9
2.8
0.6
0.6
%
0.14
12
42
13
48
2.90
2.81
11.8
11.2
0.5
0.6
%
1.37
13
48
13
48
2.90
2.81
12.2
10.8
0.9
1.4
%
1.50
13
48
5
6
8.60
2.77
1.0
1.3
—
—
—
0
0
6
10
6.23
2.73
1.0
1.0
—
—
—
0
0
5
7
7.37
2.57
4.8
2.1
—
—
—
0
0
11
39
2.99
2.54
12.3
5.3
25.2
24.3
mmol/l
0.37
11
39
12
45
2.84
2.53
3.0
2.7
2.3
1.2
%
0.79
12
45
5
8
6.45
2.39
4.8
2.0
—
—
—
0
0
5
8
6.45
2.39
4.8
2.0
—
—
—
0
0
6
13
4.78
2.30
1.0
1.0
—
—
—
0
0
6
13
4.78
2.30
4.5
1.7
—
—
—
0
0
40
259
1.79
2.28
1.4
1.3
0.4
1.8
u/ml
—
8
70
5
9
5.73
2.23
1.0
1.0
—
—
—
0
0
6
14
4.44
2.17
1.0
1.1
—
—
—
0
0
5
10
5.15
2.09
1.0
1.0
—
—
—
0
0
5
10
5.15
2.09
5.0
1.8
—
—
—
0
0
7
20
3.64
2.08
2.0
1.3
—
—
—
0
0
6
15
4.14
2.06
4.5
1.7
—
—
—
0
0
66
509
1.61
1.90
5.7
3.3
0.0
0.0
estimate
0.00
17
87
6
18
3.44
1.77
2.0
1.2
—
—
—
0
0
6
144
0.39
1.64
1.5
1.7
—
—
—
0
0
65
516
1.53
1.56
8.3
4.6
0.0
0.0
estimate
0.00
17
88
65
518
1.52
1.52
5.8
3.3
0.0
0.0
estimate
0.00
17
87
9
37
2.54
1.51
1.3
1.3
—
—
—
0
0
6
22
2.81
1.45
1.2
1.1
—
—
—
0
0
14
75
1.97
1.41
3.1
3.1
100.3
68.1
ml/min/173m2
—
6
33
50
384
1.50
1.36
5.0
3.1
26.0
24.3
ng/l
0.08
41
234
8
39
2.12
1.17
1.8
3.1
—
—
—
0
0
7
33
2.18
1.07
1.7
1.5
—
5706.0
—
0
10
27
200
1.44
0.86
1.6
1.4
—
—
—
0
0
34
266
1.38
0.80
5.8
3.6
0.0
0.0
estimate
0.00
17
86
7
41
1.75
0.71
1.4
1.2
—
—
—
0
0
7
115
0.59
0.61
8.9
6.0
—
—
—
0
0
0
20
0.00
0.61
0.0
1.3
—
7.7
—
0
13
0
22
0.00
0.60
0.0
1.2
—
3.8
—
0
10
9
134
0.65
0.55
6.2
4.1
36.6
31.4
%
—
9
87
48
416
1.25
0.53
6.4
3.4
—
—
—
0
0
84
782
1.22
0.44
4.7
3.0
58.5
45.1
u/l
0.80
84
739
8
55
1.48
0.44
1.6
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
9
66
1.39
0.39
1.8
1.5
—
—
—
0
0
18
144
1.29
0.38
1.7
1.6
—
—
—
0
0
28
242
1.20
0.31
1.6
1.5
—
—
—
0
0
83
785
1.16
0.31
4.2
3.3
—
—
—
0
0
22
257
0.83
0.30
5.1
4.7
2.4
3.0
ug/l
0.19
22
227
17
140
1.25
0.29
1.8
1.9
1.6
1.4
%
0.34
12
126
16
133
1.23
0.26
1.6
1.5
—
—
—
0
0
9
77
1.18
0.25
2.2
2.4
7.6
5.0
ug/l
—
9
65
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
106
1035
1.14
0.17
43.7
13.0
40.3
40.6
%
0.21
85
813
19
210
0.89
0.13
1.2
1.2
1.3
8.5
u/ml
—
6
90
19
206
0.91
0.09
4.3
4.3
20.6
22.7
%
0.24
13
87
5
60
0.83
0.08
1.4
1.3
—
—
—
0
0
21
206
1.02
0.00
1.3
1.3
12.3
54.6
iu/ml
—
7
70
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
17.5
—
0
5
0
5
0.00
0.00
0.0
1.0
—
0.0
—
0
5
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_HEREDHYPOGAMMA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_HEREDHYPOGAMMA | 3.534 [2.19, 5.71] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.052 |
During the follow-up period (1.1.1998 — 31.12.2019), 61 out of 290 females with D3_HEREDHYPOGAMMA died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have D3_HEREDHYPOGAMMA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.309% | No data |
| 5 | 1.859% | No data |
| 10 | 4.472% | No data |
| 15 | 8.584% | No data |
| 20 | 14.501% | No data |
Relationships between endpoints
↥Index endpoint: D3_HEREDHYPOGAMMA – Hereditary hypogammaglobulinemia
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data